AcelRx Pharmaceuticals Inc


Irrational Opioid Crisis Volatility Nipping at AcelRx Pharmaceuticals Inc (ACRX) Presents Stellar Entry Point

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) investors are getting enthusiastic again after the biotech firm’s Phase 3 IAP312 clinical trial of Zalviso, approved in the …

AcelRx Pharmaceuticals Inc (ACRX) Could Face Opioid Heat from FDA with Zalviso, Worries Roth Capital

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) investors are quaking today in the upshot of earnings not so far off the mark from second quarter expectations. …

Cowen Raises Red Flag on AcelRx Pharmaceuticals Inc (ACRX) Ahead of Dsuvia’s PDUFA

The next key catalyst for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is Dsuvia’s Prescription Drug User Fee Act (PDUFA) on October 12, 2017 for the …

AcelRx Pharmaceuticals Inc (ACRX) Announces Key Results from Phase 3 Study of ZALVISO

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) reported key results from the Phase 3 IAP312 study of ZALVISO® (sufentanil sublingual tablet system), an investigational product candidate …

Will AcelRx Pharmaceuticals, Inc. (ACRX) Win FDA Approval For Dsuvia? Depends Who You Ask

Will the FDA grant its key blessing to AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) come October 12th for its lead acute pain reliever drug candidate, …

AcelRx Pharmaceuticals Inc (ACRX) Names Raffi Asadorian Chief Financial Officer

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced the appointment of Raffi Asadorian as chief financial officer, effective August 16, 2017. Mr.

Jefferies Sees Strong Upside in AcelRx Pharmaceuticals’ Shares and Set a $7 Price Target

In a research report issued Friday, Jefferies analyst Matthew Andrews assumed coverage on shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), with a Buy rating and a $7.00 price …

Company Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Submits New Drug Application for ARX-04 for the Treatment of Moderate-To-Severe Acute Pain

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) announced that it has submitted a New Drug Application (NDA) under section 505(b)(2) with the U.S.

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Brings on Two More Acute Pain Experts to Analyst and Investor Event

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) announced an update to the agenda for its December 1, 2016 Analyst & Investor Event. Dr.

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Unveiling Results of ARX-04 SAP303 Study in Post-Operative Setting at the Annual ASRA Pain Medicine Meeting

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced an upcoming presentation at the 15th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and …